STSolomon Tadesse

Solomon Tadesse

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Solomon Tadesse has a total of 109 co-authors. Here are the top co-authors by number of shared publications:

  • Shudong Wang

    Drug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia

    7 shared publications
  • Mingfeng Yu

    Drug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia

    4 shared publications
  • Andrii Monastyrskyi

    Department of Drug Discovery, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida

    3 shared publications
  • Ariaya Hymete

    Affiliation Addis Ababa University, College of Health Sciences, Department of Pharmaceutical Chemistry and Pharmacognosy, Addis Ababa, Ethiopia

    3 shared publications
  • Hugo Albrecht

    Centre for Pharmaceutical Innovation (CPI), School of Pharmacy and Biomedical Sciences, College of Health, Adelaide University, Adelaide, SA 5000, Australia

    3 shared publications
  • Malika Kumarasiri

    Centre for Drug Discovery and Development, School of Pharmacy and Medical Sciences, Cancer Research Institute, University of South Australia, Adelaide, SA 5001, Australia

    3 shared publications

Latest Publications

  • Open Access

    Evaluation of analgesic and anti-inflammatory activities of the root extract of Grewia schweinfurthii Burret and its major chemical constituents

    by Abdi Leta Gemechu, Mirutse Giday, Solomon Tadesse, Ariaya Hymete

    Despite the widespread use of conventional analgesic and anti-inflammatory drugs, their clinical utility is often limited by adverse effects, necessitating the search for safer alternatives from medicinal plants. This study investigated the analgesic and anti-inflammatory activities of the 80% methanolic root extract of Grewia schweinfurthii Burret and an isolated bioactive compound using established rodent models. Air-dried roots were extracted by maceration with 80% methanol, and acute oral toxicity was evaluated following OECD guidelines. Analgesic activity was assessed using the acetic acid–induced writhing and hot plate models in mice, while anti-inflammatory activity was evaluated using carrageenan-induced paw edema in rats. A bioactive compound, 4 (2ʺ-(4′-isopropylphenyl) propan-2ʺ-yl)-2,3-dihydrofuran, was isolated via column chromatography and tested for anti-inflammatory activity. In the writhing test, the extract produced significant (p < 0.001) dose-dependent inhibition of abdominal constrictions, with 13.90%, 56.81%, and 75.48% inhibition at 100, 200, and 400 mg/kg, respectively, compared to 80.77% inhibition by aspirin (150 mg/kg). In the hot plate model, the 400 mg/kg dose significantly prolonged latency time from a baseline of 5.67 ± 0.33 s to 9.17 ± 1.01 s at 120 min (p < 0.05), indicating central analgesic activity. In the carrageenan-induced paw edema model, the extract demonstrated marked anti-inflammatory effects, with 93% inhibition at 400 mg/kg at the 5th hour, comparable to indomethacin (95% inhibition). The isolated compound exhibited significant dose-dependent anti-inflammatory activity, achieving 75% inhibition at 40 mg/kg at 5 hours (p < 0.001). Overall, the findings demonstrate that G. schweinfurthii root extract and its isolated compound possess significant peripheral and central analgesic as well as potent anti-inflammatory activities, supporting the plant’s traditional use; however, further mechanistic, toxicological, and pharmacokinetic studies are required before clinical relevance can be established.


  • Structure–Activity and Structure–Degradation Relationship Studies of 2-Amino-6-(benzimidazol-2-ylmethyl)-N9-heteroarylpurines as Potent and Selective CDK12/13 Inhibitors and Cyclin K Degraders

    by Thiyagamurthy Pandurangan, Solomon Tadesse Zeleke, Anna Iermolaieva, Pompom Ghosh, John Mosior, Luxin Sun, Dylan Grassie, Maximilian Schmitz, Mahalakshmi Naidu Kalaga, William Albritton, et al.

    Targeted modulation of the CDK12/CycK complex offers a compelling avenue for exploiting transcriptional addiction in cancer. Among emerging strategies, small molecule CDK12/13 inhibitors that induce selective CycK degradation via proximity-based mechanisms are demonstrating encouraging preclinical results. However, the rational design of molecular glue degraders remains challenging as the structural principles governing efficient target degradation are not always well understood. Here, we report the design, synthesis, structure-activity, and structure-degradation relationship studies of a series of highly potent and selective N9-heteroaryl purine-based CDK12/13 inhibitors, SR-4835 and its optimized analog SR-5037, that act as molecular glue degraders of CycK. In vitro target engagement and in vivo PK/PD studies in mice demonstrate dose-dependent CycK degradation that closely tracks systemic compound exposure. These findings establish CycK as a suitable proximal PD biomarker for this inhibitor class and highlight purine-based scaffolds as a rational framework for the development of bifunctional CDK12/CycK inhibitors and degraders.


  • Open Access

    Antitrypanosomal Activity and Molecular Docking Studies of Lobetyolin From Lobelia rhynchopetalum Hemsl. Root Extract Against Trypanosoma congolense Field Isolates

    by Selamawit Yimer, Eyael Tewelde, Daniel Bisrat, Solomon Tadesse, Mariamawit Y. Yeshak

    Currently available drugs for trypanosomiasis are few, and their use is limited by toxicity and growing resistance. This highlights the need for safer and more effective alternatives. In this study, the in vitro and in vivo antitrypanosomal activities of an 80% methanol root extract of Lobelia rhynchopetalum and its major constituent were evaluated against Trypanosoma congolense field isolates. Phytochemical separation of the extract yielded lobetyolin (a polyacetylene compound), confirmed through spectroscopic analysis. At 4 mg/mL, both the crude extract and lobetyolin inhibited parasite motility, with lobetyolin acting slightly faster (25 min) than the extract (30 min). The blood incubation assay demonstrated dose‐dependent protection, with 4 mg/mL of DA, the lobetyolin‐rich extract, or pure lobetyolin preventing infection, while lower doses only delayed parasitemia. In vivo testing showed that lobetyolin at 100 mg/kg exhibited stronger activity than the crude extract at 400 mg/kg. Molecular docking demonstrated that lobetyolin binds strongly to the homology‐modeled trypanothione reductase (TR) enzyme of T. congolense , achieving a Glide score of −8.002 kcal/mol, which is close to that of the native ligand (−8.307 kcal/mol). This suggests that lobetyolin may inhibit TR, thereby disrupting the parasite′s redox balance essential for survival. Overall, these findings provide the first evidence supporting the antitrypanosomal activity of L. rhynchopetalum root extract and lobetyolin, providing scientific support to the plant′s traditional use. Further studies are needed to fully validate its therapeutic potential.


  • Cyclin‐Dependent Kinase 11: Cellular Functions and Potential Therapeutic Applications

    by Janhabee Shrestha, Jason Blanchard, Solomon Tadesse

    Cyclin‐dependent kinase 11 (CDK11) is a multifunctional serine/threonine protein kinase that plays a pivotal role in transcription and pre‐mRNA splicing. It phosphorylates serine 2 of RNA polymerase II C‐terminal domain, thereby promoting transcriptional elongation and 3′‐end processing of replication‐dependent histone genes. CDK11 also contributes to proper chromosome segregation during mitosis. As a key regulator of global pre‐mRNA splicing, CDK11 activates the spliceosome, by phosphorylating Splicing Factor 3B Subunit 1, a core component of the U2 small nuclear ribonucleoprotein complex. Given the tight coupling between splicing, transcription, and cell proliferation, inhibition of CDK11 is hypothesized to impair both general transcription and cell cycle progression. CDK11 drives cancer cell proliferation, promotes HIV‐1 mRNA 3′‐end processing to enhance viral replication, and contributes to tau phosphorylation in Alzheimer's disease. Owing to itscentral role in key cellular processes and its dysregulation in various diseases, CDK11 has emerged as a compelling therapeutic target. This review provides a comprehensive overview of the biological functions and regulatory mechanisms of CDK11, discusses its role in cancer, viral, and neurodegenerative diseases, and highlights advances in the discovery and development of CDK11 inhibitors, including OTS964, which has expanded our understanding of the biological functions of CDK11 and its prospects as a cancer‐specific vulnerability.


  • Synthesis, Antibacterial Activity and In Silico Study of 1-(2-ethyl acetate)-2-styryl 5-nitroimidazole Derivatives

    by Misgana Aragaw, Sileshi Degu, Abiy Abebe, Mekonnen Abebayehu, Kibrom Gebreheiwot Bedane, Daniel Bisrat, Solomon Tadesse

    Background: For more than six decades, the use of metronidazole has been limited to anaerobic microorganisms. However, there are accounts of metronidazole derivatives exhibiting strong effectiveness against facultative anaerobic bacteria, suggesting that there may be another mechanism of action for metronidazole. Recent studies have shown that the enzyme FabH (β-ketoacyl-acyl carrier protein synthase III), responsible for the first step of fatty acid biosynthesis (FAB), is a promising target for nitroimidazole derivatives that can be used as an effective anti-infective agent. Objective: This study aimed to synthesize 1-(2-ethyl acetate)-2-styryl nitroimidazole derivatives and evaluate their in vitro and in silico antibacterial activity Methods: We synthesized 2-styryl 5-nitroimidazole derivatives by first condensing metronidazole with benzaldehydes and then carrying out an acetylation reaction. We evaluated the antimicrobial activity of the synthesized compounds against three Gram-positive bacterial strains (Staphylococcus aureus, Staphylococcus epidermidis, and Streptococcus agalactiae) and three Gram-negative bacterial strains (Escherichia coli, Pseudomonas aeruginosa and Klebsiella pneumoniae) using a two-fold serial dilution MTT (3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyltetrazolium bromide) assay. Results: Compounds 2 and 4 exhibited the highest level of antibacterial effectiveness, with minimum inhibitory concentrations (MIC) of 1.56 μg/mL against S. agalactiae and 3.13 μg/mL against P. aeruginosa. Compounds 2 and 4 also exhibited potent activity against K. pneumonia, with an MIC value of 6.25 μg/mL and 12.5 μg/mL, respectively. Molecular docking studies revealed that both compounds have favorable hydrophobic and electrostatic interactions with conserved residues in the binding site of the E. coli β-Ketoacyl-acyl carrier protein synthase III (FabH) complex. Conclusion:: Acetylation of 2-styryl-5-nitroimidazoles improved both their biological activity and binding interaction with the target protein


  • Ranunculin, Protoanemonin, and Anemonin: Pharmacological and Chemical Perspectives

    by Betelhem Sirak, Misgana Aragaw, Solomon Tadesse

    Ranunculin, a glucoside, serves as a chemotaxonomic marker in Ranunculaceae plants. When these plants are damaged, an enzyme β−glucosidase triggers the conversion of ranunculin into protoanemonin through hydrolysis. Subsequently, protoanemonin undergoes cyclodimerization to form anemonin. The inherent instability of ranunculin and the rapid dimerization of protoanemonin render them unsuitable for use in biological assays. Conversely, anemonin stands out as the optimal molecule for bioassays and demonstrates diverse biological properties, including anti-inflammatory, anti-infective, and anti-oxidant effects. Among these, anemonin exhibits the greatest promise in addressing arthritis, cerebral ischemia, and ulcerative colitis. Its potential medical uses are enhanced by its capacity to inhibit nitric oxide synthesis and successfully counteract lipopolysaccharide-induced inflammation. This review describes the chemistry and biological properties of anemonin and its precursors, including discussions on extraction, isolation, synthesis, and investigations into bioactivity and pharmacokinetics.


  • Open Access

    Discovery and design of molecular glue enhancers of CDK12–DDB1 interactions for targeted degradation of cyclin K

    by Pompom Ghosh, Maximilian Schmitz, Thiyagamurthy Pandurangan, Solomon Tadesse Zeleke, Sean Chin Chan, John Mosior, Luxin Sun, Vinayak Palve, Dylan Grassie, Kanchan Anand, et al.

    De novo design of molecular glues transforming CDK12 inhibitors, including dinaciclib, into cyclin K degraders.


  • Antidiarrheal coumarins from Psydrax schimperianus (A. Rich.) Bridson roots

    by Getahun Damissie, Ketema Tolossa, Ariaya Hymete, Solomon Tadesse


  • Open Access

    Drug Discovery and Development for Soil-Transmitted Helminthiasis: Current Anthelmentics and Compounds in the Pipeline

    by Eyael Tewelde, Solomon Tadesse

    Soil-transmitted helminthiasis (STH), one of 20 neglected tropical diseases, afflicts about a quarter of the world’s population. A handful of medications, albendazole, mebendazole, pyrantel pamoate, levamisole, and ivermectin, have long constituted the cornerstone of therapy for these infections in both humans and animals. The continuous and long-term reliance on these small range of compounds has led to the emergence of drug resistance in many helminthic strains in animals. The threat of resistance also seems inevitable in humans thereby hampering the World Health Organization’s efforts to control or eradicate these neglected tropical illnesses. Hence, there is an urgent need for the discovery and development of new treatment options with broad spectrum activity against various helmintic infections that act via novel mechanisms of action. Different strategies are employed in this endeavor which include the identification of promising compounds from natural and synthetic origin, drug repurposing and modification of existing drugs, and vaccine development. The prospect of a “pan-anthelmintic vaccine” also seems encouraging, despite the various obstacles facing the development of vaccines. Here we discuss drug discovery and development efforts for STH.